Pharmaids Pharmaceuticals Ltd (524572)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Pharmaids Pharmaceuticals' revenue was ₹4.1 Cr (-38.1% year on year, -42.6% on the previous quarter), and net profit ₹1.9 Cr (against a loss a year earlier); the operating margin was -18.1%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹4.1 | -38.1% | -42.6% |
| Operating profit | ₹-0.7 | loss narrowed | loss widened |
| Net profit | ₹1.9 | from loss | from loss |
| EPS (₹) | 0.63 | from loss | from loss |
| Operating margin | -18.1% | — | — |
📢 Recent Corporate Announcements
Pharmaids Pharmaceuticals Limited has submitted its 37th Annual Report along with the Notice convening its Annual General Meeting on September 11, 2026. For FY 2025-26, the company reported consolidated total revenue of Rs 28.17 crore compared to Rs 19.55 crore in FY 2024-25. Consolidated net loss for the year stood at Rs 11.57 crore versus a loss of Rs 13.51 crore in the previous fiscal. The cut-off date for e-voting eligibility is September 4, 2026.
- 37th AGM scheduled to be held on Friday, September 11, 2026, via electronic means
- E-voting period commences on September 8, 2026, and ends on September 10, 2026 (cut-off: September 4, 2026)
- FY26 consolidated revenue reached Rs 28.17 crore compared to Rs 19.55 crore in FY25
- FY26 consolidated net loss stood at Rs 11.57 crore against Rs 13.51 crore in FY25
- Paid-up share capital remained constant at Rs 35.27 crore (3.53 crore equity shares of Rs 10 each)
Pharmaids Pharmaceuticals has issued the notice convening its 37th Annual General Meeting (AGM) on Friday, September 11, 2026, alongside its Annual Report for FY 2025-26. The cut-off date for e-voting eligibility is September 4, 2026, with remote e-voting running from September 8 to September 10, 2026. For FY26, the company reported consolidated total revenue of ₹28.17 crore compared to ₹19.55 crore in FY25, while consolidated net loss stood at ₹11.57 crore vs ₹13.51 crore in the previous year.
- 37th Annual General Meeting scheduled for September 11, 2026, at 12:00 noon (IST)
- Remote e-voting open from September 8, 2026, to September 10, 2026, with cut-off date on September 4, 2026
- Consolidated revenue increased to ₹28.17 crore in FY26 from ₹19.55 crore in FY25
- Consolidated net loss for FY26 narrowed to ₹11.57 crore compared to ₹13.51 crore in FY25
- No dividend recommended on equity shares for the financial year ended March 31, 2026
Pharmaids Pharmaceuticals has approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company is currently loss-making, with a TTM net profit of Rs -12 Cr and an operating profit margin of -48.6%. Investors should note the company's strategic shift toward the Contract Research, Development and Manufacturing Organization (CRDMO) segment to offset pricing pressures in generics. The board also approved the notice for the 37th Annual General Meeting (AGM) to be held via video conferencing.
- Board approved unaudited financial results for the quarter ended June 30, 2026, on August 12, 2026.
- Company reported a TTM revenue of Rs 28 Cr against a market capitalization of Rs 119 Cr.
- TTM net loss stands at Rs 12 Cr, reflecting ongoing operational challenges in the generic space.
- Promoter holding remains stable at 32.99% as of the June 2026 quarter.
- Notice for the 37th Annual General Meeting (AGM) was approved by the board.
Pharmaids Pharmaceuticals approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company also announced its 37th Annual General Meeting (AGM) will be conducted via video conferencing. While the specific quarterly figures were not detailed in the summary letter, the company enters this period with a TTM revenue of ₹28 Cr and a net loss of ₹12 Cr. Investors should scrutinize the full results for any improvement in the -48.6% operating margin.
- Board approved unaudited financial results for the quarter ended June 30, 2026
- Scheduled the 37th Annual General Meeting (AGM) to be held via Video Conferencing
- The board meeting concluded within 78 minutes, starting at 04:57 P.M. and ending at 06:15 P.M.
- Statutory Auditors M/s PPKG & Co issued a Limited Review Report on the results
Pharmaids Pharmaceuticals has scheduled a board meeting for August 12, 2026, to approve its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company is currently navigating a challenging financial phase with a TTM revenue of ₹28 Cr and a net loss of ₹12 Cr. The trading window for insiders has been closed since July 1, 2026, and will reopen 48 hours after the results are announced. Investors will be looking for signs of margin recovery, as the current TTM operating profit margin stands at -48.6%.
- Board meeting scheduled for August 12, 2026, to approve Q1 FY27 results
- Trading window closed from July 1, 2026, until 48 hours post-result declaration
- Company reported a TTM net loss of ₹12 Cr against a revenue of ₹28 Cr
- Operating profit margin remains deeply negative at -48.6% as per TTM data
- Market capitalization stands at ₹114 Cr with a debt-to-equity ratio of 0.49
Financial Performance
Revenue Growth by Segment
Revenue from operations for FY 2024-25 was INR 2.34 Cr (Rs. 234.09 lakhs). The company is transitioning into a science-based entity focusing on Contract Research, Development and Manufacturing Organization (CRDMO) services, though specific percentage growth by segment is not disclosed.
Geographic Revenue Split
The company operates in both domestic and international markets with a special focus on CRDMO expansion, but the exact percentage split between regions is not disclosed in available documents.
Profitability Margins
Operating Profit Margin was -2.75% in FY 2024-25, a 99% variance from -207.33% in FY 2023-24. Net Profit Ratio was -3.11% in FY 2024-25, a 98% variance from -178.37% in the previous year. These improvements are attributed to increased turnover.
EBITDA Margin
Operating Profit Margin improved to -2.75% from -207.33% YoY. Despite the margin improvement, the company reported a net loss of INR 7.28 Cr (Rs. 727.92 lakhs) for FY 2024-25, which is a 47% increase in loss compared to INR 4.95 Cr (Rs. 494.98 lakhs) in FY 2023-24.
Credit Rating & Borrowing
Debt-Equity Ratio increased by 251% to 0.62 in FY 2024-25 from 0.18 in FY 2023-24 due to increased debt. Interest Coverage was -2.90 days, an 83% variance from -16.72 days YoY, reflecting higher interest expenses.
Operational Drivers
Raw Material Costs
Purchases and inventory increased during the year, leading to a 73% decrease in Inventory Turnover to 907.55 times from 3357.12 times YoY.
Strategic Growth
Growth Strategy
Growth will be achieved by prioritizing the Contract Research, Development and Manufacturing Organization (CRDMO) segment, expanding into Good Laboratory Practices (GLP) Developmental Services, and leveraging synergies from acquisitions like Adita Bio Sys, Siri Lab Vivio Diet, Spring Labs, and Anugraha Chemicals.
Products & Services
Contract Research, Development and Manufacturing Organization (CRDMO) services, product discovery, research, development, manufacturing, testing, analytical services, and new chemical entities.
Brand Portfolio
Pharmaids Pharmaceuticals Limited, Adita Bio Sys Private Limited, Siri Lab Vivio Diet Private Limited, Spring Labs, and Anugraha Chemicals.
New Products/Services
The company is creating a pipeline of new chemical entities and difficult-to-manufacture molecules through substantial R&D investments to meet evolving patient needs.
Market Expansion
Targeting domestic and international markets with a focus on emerging markets characterized by aging populations and rising healthcare spending.
Strategic Alliances
Successful integration of brands from Adita Bio Sys Private Limited, Siri Lab Vivio Diet Private Limited, Spring Labs, and Anugraha Chemicals to diversify the portfolio.
External Factors
Industry Trends
The global pharma market is growing due to aging populations and chronic diseases. Trends include increased R&D focus, AI integration for speedier results, and the rise of digital health technologies.
Competitive Landscape
Key competition comes from generic drug manufacturers and other global CRDMO organizations.
Competitive Moat
Moat is built on a diversified service portfolio and a transition to science-based R&D, which helps maintain a competitive edge against generic manufacturers.
Macro Economic Sensitivity
The company is sensitive to global healthcare spending trends and the prevalence of chronic diseases like cancer and diabetes, which drive demand for its CRDMO services.
Consumer Behavior
Increasing digitization and the traction of e-pharmacy and pharmacy chains are transforming how healthcare services are consumed.
Regulatory & Governance
Industry Regulations
Heavily regulated by guidelines related to drug development, manufacturing, and marketing. Non-compliance can result in significant fines, penalties, and reputational damage.
Environmental Compliance
The company aims to operate as an ecologically conscious firm, though specific ESG compliance costs are not disclosed.
Taxation Policy Impact
Governments are providing tax incentives and funding for R&D to support the pharmaceutical industry's development.
Legal Contingencies
Lawsuits related to drug efficacy, safety, and potential side effects are noted as a concern that could result in significant legal costs and settlements, though specific case values are not disclosed.
Risk Analysis
Key Uncertainties
Regulatory changes, patent expirations, pricing pressures, and competition from generics are primary business risks.
Geographic Concentration Risk
The company is expanding its reach in India and seeking international market expansion, particularly in emerging markets.
Technology Obsolescence Risk
The company is actively exploring AI and digital health technologies to mitigate the risk of technological obsolescence in drug discovery.
Credit & Counterparty Risk
Debtors Turnover was 24.36 days in FY 2024-25, compared to zero trade receivables in the previous year, indicating a new but manageable credit exposure.
